

## **Clinical outcome for Episealer® to be presented at the annual meeting of the Danish Orthopaedic Society (DOS) in Copenhagen**

Episurf Medical (Nasdaq: EPIS B) today announces that the scientific abstract "*Clinical results of an individualized mini-metal implant for focal cartilage lesions in the knee*" by Prof. Martin Lind et al. will be presented at the DOS congress in Copenhagen, Denmark, which will take place on October 24 - 26, 2018.

The clinical outcome for patients undergoing treatment for femoral chondral defects using the individualised mini-metal implant Episealer® is presented.

The abstract shows excellent early clinical results from the treatment of focal symptomatic cartilage lesions on the femoral condyles and in the trochlea area with a second-generation individualised metal implant.

"Clinical results from the use of Episealer® is being requested by the orthopaedic community, and we are proud that clinical results from the use of our technology once again is recognised at an orthopaedic congress", says Pål Ryfors, CEO of Episurf Medical.

### **For more information, please contact:**

Pål Ryfors, CEO, Episurf Medical  
Tel: +46 (0) 709 62 36 69  
Email: [pal.ryfors@episurf.com](mailto:pal.ryfors@episurf.com)

### **About Episurf Medical**

*Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical's Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical's *μiFidelity®* system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: [wwwepisurf.com](http://wwwepisurf.com).*